Clinical benefit response in pancreatic cancer trials revisited.

Oncology research and treatment

Volumn 37, Issue 1-2, 2014, Pages 42-48

  Bernhard, Jürg ^a   Dietrich, Daniel ^b   Glimelius, Bengt ^b   Bodoky, György ^b   Scheithauer, Werner ^b   Herrmann, Richard ^b  

^a SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; GEMCITABINE;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG THERAPY; EPIDEMIOLOGY; FEMALE; HUMAN; INCIDENCE; KARNOFSKY PERFORMANCE STATUS; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PAIN; PALLIATIVE THERAPY; PANCREAS TUMOR; PHASE 3 CLINICAL TRIAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CAUSALITY; COMORBIDITY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG THERAPY; FEMALE; FLUOROURACIL; HUMANS; INCIDENCE; KARNOFSKY PERFORMANCE STATUS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PAIN; PALLIATIVE CARE; PANCREATIC NEOPLASMS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84910121971     PISSN: None     EISSN: 22965262     Source Type: Journal    
DOI: 10.1159/000357965     Document Type: Article

References (0)